Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivo
Open Access
- 1 March 2000
- journal article
- review article
- Published by Springer Nature in Molecular Medicine
- Vol. 6 (3) , 165-178
- https://doi.org/10.1007/bf03402112
Abstract
Human breast carcinoma cell lines express high-affinity interleukin-4 receptors (IL-4R). We examined the expression and structure of these receptors on primary and cultured breast carcinoma cell lines and normal breast epithelial cells. We also tested the antitumor activity in vitro and in vivo of a fusion protein comprised of circular permuted IL-4 and truncated Pseudomonas exotoxin, termed IL-4(38-37)-PE38KDEL. Eight different primary cell cultures and cell lines of human breast carcinomas were examined for the expression of IL-4R by radiolabeled binding, reverse transcription polymerase chain reaction (RT-PCR) and Northern analyses, and subunit structure by crosslinking studies. The antitumor activity of IL-4 toxin was tested in vitro by cytotoxicity assays and in vivo in a xenograft model in immunodeficient animals. 125I-IL-4 specifically bound to primary cell cultures and cell lines with a Kd ranging between 0.2 and 1 nM. Breast tumor cells were found to express IL-4Rβ and IL-13Rα′ chains, but not IL-2Rγc chain. These cells were highly sensitive to the cytotoxic effect of IL-4(38-37)-PE38KDEL. The IC50 (concentration inhibiting protein synthesis by 50%) ranged between approximately 0.005–1.5 nM. A normal breast epithelial cell culture was not sensitive to the cytotoxic activity of IL-4(38-37)-PE38KDEL. MDA-MB231 human breast carcinoma cell line formed a rapidly growing tumor in nude mice. Intratumor and intraperitoneal administration of IL-4(38-37)-PE38KDEL caused a dose dependent regression of established tumors. A control toxin, anti-Tac(Fv)-PE38KDEL, targeted to the IL-2 receptor α chain did not cause regression of these tumors. These results suggest that IL-4(38-37)-PE38KDEL may be a useful agent for targeting of IL-4 receptor positive human breast carcinomas and further studies should be performed to explore fully its potential.Keywords
This publication has 34 references indexed in Scilit:
- Structure of IL-13 Receptor: Analysis of Subunit Composition in Cancer and Immune CellsBiochemical and Biophysical Research Communications, 1997
- Receptors for Interleukin (IL)-4 Do Not Associate with the Common γChain, and IL-4 Induces the Phosphorylation of JAK2 Tyrosine Kinase in Human Colon Carcinoma CellsJournal of Biological Chemistry, 1995
- Up‐regulation of intercellular adhesion molecule 1 (ICAM‐1) on human renal cell carcinoma cells by interleukin‐4International Journal of Cancer, 1995
- Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and ActivityBiochemistry, 1994
- Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimericPseudomonas exotoxinInternational Journal of Cancer, 1994
- Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric proteinInternational Journal of Cancer, 1994
- Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) on human renal cell carcinomaClinical and Experimental Immunology, 1994
- Human Renal Cell Carcinoma Cells Are Sensitive to the Cytotoxic Effect of a Chimeric Protein Composed of Human Interleukin-4 and Pseudomonas ExotoxinCellular Immunology, 1994
- Interleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-4 ReceptorScience, 1993
- Interleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-7 ReceptorScience, 1993